NCT00466466 - Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2010

Conditions

Small-Cell Lung Cancer

Interventions

DRUG

Everolimus

RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.

Trial Locations (6)

72703

Highlands Oncology Group, Fayetteville

78229

Cancer Therapy and Research Center at UTHSCSA, San Antonio

80045

University of Colorado Health Sciences Center, Aurora

02115

Dana Faber Cancer Institute, Boston

77030-4009

MD Anderson Cancer Center, Houston

Unknown

Novartis Investigative Site, Paris